GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (FRA:JX7) » Definitions » Additional Paid-In Capital

Embecta (FRA:JX7) Additional Paid-In Capital : €37 Mil(As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Embecta Additional Paid-In Capital?


Embecta's quarterly additional paid-in capital increased from Sep. 2023 (€26 Mil) to Dec. 2023 (€31 Mil) and increased from Dec. 2023 (€31 Mil) to Mar. 2024 (€37 Mil).

Embecta's annual additional paid-in capital increased from Sep. 2021 (€0 Mil) to Sep. 2022 (€10 Mil) and increased from Sep. 2022 (€10 Mil) to Sep. 2023 (€26 Mil).


Embecta Additional Paid-In Capital Historical Data

The historical data trend for Embecta's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embecta Additional Paid-In Capital Chart

Embecta Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
Additional Paid-In Capital
- - - 10.10 26.14

Embecta Quarterly Data
Sep19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.91 21.41 26.14 30.63 36.52

Embecta Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Embecta Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Embecta's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Embecta (FRA:JX7) Business Description

Traded in Other Exchanges
Address
300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.

Embecta (FRA:JX7) Headlines

No Headlines